{"id":"xl092","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CDK4/6, XL092 disrupts the cell cycle progression, leading to cell cycle arrest and apoptosis in cancer cells. This mechanism is particularly effective in treating certain types of cancer, such as breast cancer.","oneSentence":"XL092 is a small molecule inhibitor of the CDK4/6 pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:11.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07227402","phase":"PHASE3","title":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-26","conditions":"Renal Cell Carcinoma","enrollment":904},{"nctId":"NCT07489495","phase":"PHASE3","title":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-04-17","conditions":"Carcinoma, Renal Cell","enrollment":758},{"nctId":"NCT06943755","phase":"PHASE2, PHASE3","title":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-07-21","conditions":"Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)","enrollment":440},{"nctId":"NCT07484139","phase":"PHASE2","title":"H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-05","conditions":"Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer","enrollment":26},{"nctId":"NCT07049926","phase":"PHASE1, PHASE2","title":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-20","conditions":"Renal Cell Carcinoma","enrollment":140},{"nctId":"NCT06863311","phase":"PHASE2","title":"Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC","status":"RECRUITING","sponsor":"Karie Runcie","startDate":"2026-03-13","conditions":"Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma","enrollment":70},{"nctId":"NCT07470489","phase":"PHASE2","title":"A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-09-30","conditions":"Anaplastic Thyroid Cancer","enrollment":12},{"nctId":"NCT05176483","phase":"PHASE1","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","status":"RECRUITING","sponsor":"Exelixis","startDate":"2021-12-14","conditions":"Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)","enrollment":1314},{"nctId":"NCT07193550","phase":"PHASE2","title":"A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-12-05","conditions":"Bone Sarcomas","enrollment":70},{"nctId":"NCT07428616","phase":"PHASE2","title":"A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","status":"NOT_YET_RECRUITING","sponsor":"Exelixis","startDate":"2026-05","conditions":"Meningioma","enrollment":100},{"nctId":"NCT06571734","phase":"PHASE2","title":"XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2024-09-19","conditions":"Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma","enrollment":29},{"nctId":"NCT06968988","phase":"PHASE1","title":"Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-01-05","conditions":"Metastatic Soft-tissue Sarcoma","enrollment":18},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT06795009","phase":"PHASE1","title":"Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-10-17","conditions":"Uterine Cancer, Endometrial Cancer","enrollment":36},{"nctId":"NCT06568562","phase":"PHASE2","title":"XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-12-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":32},{"nctId":"NCT06912087","phase":"PHASE1","title":"Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-09-29","conditions":"Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local","enrollment":36},{"nctId":"NCT06698250","phase":"PHASE2","title":"Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2024-12-18","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06902376","phase":"PHASE1","title":"XL092 and Cemiplimab in BRAF WT Thyroid Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-06-03","conditions":"Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors","enrollment":12},{"nctId":"NCT06794229","phase":"PHASE2","title":"Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis","status":"RECRUITING","sponsor":"Qian Qin","startDate":"2025-10-30","conditions":"Locally Advanced Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT06957431","phase":"PHASE1","title":"Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-10-22","conditions":"Advanced Leiomyosarcoma, Adipocytic Sarcoma, Advanced Liposarcoma","enrollment":18},{"nctId":"NCT05425940","phase":"PHASE3","title":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2022-09-07","conditions":"Colorectal Cancer","enrollment":901},{"nctId":"NCT07218666","phase":"PHASE2","title":"Zanzalintinib in Men With Aggressive Variant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Deepak Kilari","startDate":"2026-05","conditions":"Aggressive Variant Prostate Carcinoma","enrollment":30},{"nctId":"NCT06082167","phase":"PHASE2, PHASE3","title":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2024-06-07","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":600},{"nctId":"NCT05678673","phase":"PHASE3","title":"Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2023-01-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":317},{"nctId":"NCT07043608","phase":"PHASE2","title":"Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases","status":"NOT_YET_RECRUITING","sponsor":"Kelly Fitzgerald, MD","startDate":"2025-09-30","conditions":"Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic","enrollment":20},{"nctId":"NCT07042919","phase":"PHASE1, PHASE2","title":"Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-04","conditions":"Advanced Hepatocellular Carcinoma, Cirrhosis, Stage III Hepatocellular Carcinoma AJCC v8","enrollment":53},{"nctId":"NCT06962332","phase":"PHASE1","title":"Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)","status":"RECRUITING","sponsor":"Exelixis","startDate":"2025-05-13","conditions":"Hepatic Impairment, Moderate Hepatic Impairment","enrollment":20},{"nctId":"NCT06191796","phase":"PHASE1","title":"Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)","status":"TERMINATED","sponsor":"Exelixis","startDate":"2024-01-25","conditions":"Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors","enrollment":25},{"nctId":"NCT06959641","phase":"PHASE2","title":"XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2025-06-06","conditions":"Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma, Locally Advanced Thyroid Gland Follicular Carcinoma","enrollment":33},{"nctId":"NCT03845166","phase":"PHASE1","title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2019-03-20","conditions":"Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma","enrollment":325}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zanzalintinib"],"phase":"phase_3","status":"active","brandName":"XL092","genericName":"XL092","companyName":"UNC Lineberger Comprehensive Cancer Center","companyId":"unc-lineberger-comprehensive-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XL092 is a small molecule inhibitor of the CDK4/6 pathway. Used for Metastatic breast cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}